Exco InTouch, the UK-based company specialising in mobile patient-engagement solutions for companies conducting clinical, late-phase and mHealth research, has linked up with mobile communications giant Vodafone to offer a global patient-reported outcomes (PRO) service.
The Vodafone PRO solution has the potential “radically” to improve patient compliance and data quality in clinical research, the partners say.
Since trial participants can report their experiences quickly and easily using their own mobile phone, customers will be able to gather high-quality through the service, they add.
And as over 85% of the world’s population now owns a mobile phone, the solution “is using accessible technology that is firmly embedded in many people’s lives”.
It will also be available on a global scale, leveraging Vodafone’s international footprint and its in-depth mobile and consumer insight as well as Exco InTouch’s extensive experience in patient engagement.
Vodafone chose Exco InTouch solutions because they provide “simple, non-intrusive and compliant channels of communication”, the companies explain.
This means trial sponsors and contract research organisations can find and retain the right patients through “engaging interactions and improved patient experience”, as well as offering customisable solutions to facilitate the collection of high-quality data.
Vodafone PRO can be configured for different study protocols in all phases of clinical research, allowing large volumes of patient data to be securely transferred, validated and analysed.
“With this collaboration, Vodafone is confident that we can offer our clients the most innovative and effective clinical research solutions available in the global market,” commented Axel Nemetz, the company’s head of mHealth Solutions.
Tim Davis, chief executive officer of Exco InTouch, said the agreement with Vodafone “demonstrates the extent to which mobile phone technology is increasingly being recognised by large pharmaceutical companies as an effective tool for the collection of clinical trial data”.